We are pleased to present an exclusive interview with Dana Brown, CEO and Chairman of the Board at iCAD Inc., to explore the ...

Today, we are hosting Dr. Raza Bokhari, CEO at Medicus Pharma, to explore a breakthrough innovation in skin cancer treatment—SkinJect, a novel microneedle patch designed to eradicate cancerous cells ...

Regeneron Pharmaceuticals, announced that the US FDA accepted its resubmitted Biologics License Application for odronextamab, a CD20xCD3 bispecific antibody, relapsed/refractory (R/R) follicular ...

The US FDA has approved Tislelizumab (Tevimbra) plus platinum-based chemotherapy as a first-line treatment for adult patients with unresectable or metastatic esophageal squamous cell carcinoma (ESCC) ...

KEYTRUDA® (pembrolizumab) plus standard care for resectable locally advanced head and neck squamous cell carcinoma receives FDA priority review based on KEYNOTE-689 results. The trial showed improved ...

The Phase III MATTERHORN trial demonstrated that Imfinzi (durvalumab) plus FLOT chemotherapy significantly improved event-free survival in resectable gastric and gastroesophageal junction cancers. The ...

The European Medicines Agency (EMA) committee (CHMP) has recommended approving trastuzumab deruxtecan (Enhertu), a HER2-directed antibody-drug conjugate for certain patients with metastatic breast ...

A durvalumab (Imfinzi)-based perioperative regimen has been recommended by the EMA Committee for the treatment of adults with resectable non-small cell lung cancer. The recommendation is based on ...

The innovative GO chip, developed at the University of Michigan, represents a significant leap in lung cancer treatment by enabling precise monitoring of treatment responses. In this exclusive ...

The early findings from the SERENA-6 trial indicate that oral SERD camizestrant provides a “highly statistically significant and clinically meaningful” improvement in progression-free survival for ...